Bionexus Gene Lab Corp. logo

Bionexus Gene Lab Corp. (BGLC)

Market Closed
16 Jun, 20:00
NASDAQ (CM) NASDAQ (CM)
$
2. 60
+0.1
+4%
After Hours
$
2. 65
+0.05 +1.9231%
4.3M Market Cap
- P/E Ratio
- Div Yield
15,977 Volume
- Eps
$ 2.5
Previous Close
Add Transaction
Day Range
2.43 2.6
Year Range
1.07 15.6
Want to track BGLC and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

BGLC closed today higher at $2.6, an increase of 4% from yesterday's close, completing a monthly increase of 21.4897% or $0.46. Over the past 12 months, BGLC stock lost -33.6735%.
BGLC is not paying dividends to its shareholders.
The last earnings report, released on Apr 21, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
Bionexus Gene Lab Corp. has completed 2 stock splits, with the recent split occurring on Apr 07, 2025.
The company's stock is traded on one exchange.

BGLC Chart

People also search for

SkyAI, Inc. Common Stock
$ 1.29
+3.2%
PXS
Pyxis Tankers Inc.
$ 4.52
+0.4444%
Globus Maritime Ltd.
$ 2.61
-4.7445%
Rising Dragon Acquisition Corp.
$ 6.23
-1.735%
Pioneer Power Solutions Inc.
$ 4.39
+2.8103%

Bionexus Gene Lab Corp. (BGLC) FAQ

What is the stock price today?

The current price is $2.60.

On which exchange is it traded?

Bionexus Gene Lab Corp. is listed on NASDAQ (CM).

What is its stock symbol?

The ticker symbol is BGLC.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 4.3M.

Has Bionexus Gene Lab Corp. ever had a stock split?

Bionexus Gene Lab Corp. had 2 splits and the recent split was on Apr 07, 2025.

Bionexus Gene Lab Corp. Profile

Professional Services Industry
Industrials Sector
Su-Leng Tan CEO
NASDAQ (CM) Exchange
090628306 CUSIP
MY Country
30 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

BioNexus Gene Lab Corp., founded in 2017 and headquartered in Kuala Lumpur, Malaysia, operates primarily through its subsidiary to distribute chemical raw material products across Malaysia, Indonesia, Vietnam, and other Southeast Asian countries. While its main business centers around the provision of chemical raw materials used in various manufacturing processes, the company has expanded its operations to include the development and provision of non-invasive liquid biopsy tests. These tests are designed for the early detection of biomarkers, which could indicate a potential risk of diseases. With its diverse product offerings, BioNexus Gene Lab Corp. serves a wide range of industries, including the automotive, aerospace, healthcare, and marine sectors. The company markets its products and services through multiple channels including its website, a physical warehouse, a team of marketing personnel, and a network of suppliers.

Products and Services

  • Polyester Resin SHCP 268

    A thixotropic, quick-curing unsaturated polyester resin that is marketed as a general-purpose resin. This material finds its application in various manufacturing processes due to its versatile properties.

  • Polyester Resin 9509

    This general-purpose material is primarily used in the production of marine boats and water slides, showcasing its strength in environments where durability and resistance to water are crucial.

  • Polyester Resin 2802

    Utilized as a component in the pultrusion process by certain manufacturers, this resin is integral in the creation of strong, lightweight products. Applications include handrails, bench tops, automotive and aero parts, and paneling for hospital, laboratory, industrial clean rooms. It is also used in the production of covers for various instruments used in manufacturing, highlighting its versatility and wide range of applications.

  • Non-invasive Liquid Biopsy Tests

    In addition to its chemical products, BioNexus is involved in the development and provision of innovative non-invasive liquid biopsy tests. These tests aim for early detection of biomarkers for potential disease risk, reflecting the company's engagement in healthcare and biotechnology sectors alongside its chemical manufacturing operations.

Contact Information

Address: Tower B, Vertical Business Suite
Phone: 60 1 2212 6512